NASDAQ:ALRN

Aileron Therapeutics Stock Forecast, Price & News

$1.10
+0.03 (+2.80 %)
(As of 09/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.05
$1.11
50-Day Range
$0.98
$1.27
52-Week Range
$0.91
$2.47
Volume350,604 shs
Average Volume1.90 million shs
Market Capitalization$99.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75
30 days | 90 days | 365 days | Advanced Chart
Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aileron Therapeutics logo

About Aileron Therapeutics

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

983rd out of 1,352 stocks

Pharmaceutical Preparations Industry

483rd out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

Is Aileron Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aileron Therapeutics?

Wall Street analysts have given Aileron Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aileron Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Aileron Therapeutics
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its earnings results on Tuesday, August, 10th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01.
View Aileron Therapeutics' earnings history
.

How has Aileron Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALRN stock has increased by 172.9% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALRN?

2 analysts have issued 12-month price targets for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 218.2% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 51, Pay $1.06M)
  • Mr. Richard J. Wanstall M.B.A., SVP, CFO & Treasurer (Age 52, Pay $551.69k)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 54, Pay $676.44k)
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 48)

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.81%), Renaissance Technologies LLC (1.14%), Geode Capital Management LLC (0.85%), Blair William & Co. IL (0.76%), Boothbay Fund Management LLC (0.43%) and State Street Corp (0.08%). Company insiders that own Aileron Therapeutics stock include Jeffrey Allen Bailey, Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends for Aileron Therapeutics
.

Which institutional investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and Citadel Advisors LLC.
View insider buying and selling activity for Aileron Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Aileron Therapeutics stock?

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Geode Capital Management LLC, State Street Corp, Millennium Management LLC, Boothbay Fund Management LLC, Morgan Stanley, Morgan Stanley, and Envestnet Asset Management Inc.. Company insiders that have bought Aileron Therapeutics stock in the last two years include Jeffrey Allen Bailey, Muneer A Satter, Reinhard J Ambros, and Rickenbach Josef H Von.
View insider buying and selling activity for Aileron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.10.

How much money does Aileron Therapeutics make?

Aileron Therapeutics has a market capitalization of $99.61 million. The company earns $-21,160,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 8 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

Where are Aileron Therapeutics' headquarters?

Aileron Therapeutics is headquartered at 490 Arsenal Way, Watertown MA, 02472.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.